Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 16/20 | 0.75 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.72 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.72 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12818767 | 0.96 | KCNK3 (0.78) | SLC2A1KCNK3KCNK9SLC2A2 | |
| SCHEMBL12819440 | 0.96 | KCNK3 (0.78) | SLC2A1KCNK3KCNK9SLC2A2 | |
| SCHEMBL17718963 | 0.94 | SLC2A2 (0.79) | SLC2A1KCNK3KCNK9SLC2A2 | |
| SCHEMBL17718932 | 0.92 | SLC2A1 (0.72) | SLC2A1KCNK3KCNK9SLC2A2 | |
| SCHEMBL12819219 | 0.91 | SLC2A1 (0.72) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL12819035 | 0.88 | SLC2A1 (0.85) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL12819170 | 0.88 | SLC2A1 (0.81) | SLC2A1SLC2A2 | |
| SCHEMBL17718940 | 0.87 | SLC2A1 (0.76) | SLC2A1 | |
| SCHEMBL18952321 | 0.87 | KCNK3 (0.93) | KCNK3KCNK9 | |
| SCHEMBL12819142 | 0.87 | SLC2A1 (0.78) | SLC2A1SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2691392-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM Technology Transfer GmbH (DE) | 2014-02-05 | — | — | EP | claimed |
| WO-2012130322-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | claimed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| EP-3004088-A1 | SLC2A TRANSPORTER INHIBITORS | Iomet Pharma Ltd. (GB) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014187922-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2014-11-27 | — | — | WO | disclosed |
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2691392-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM Technology Transfer GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012130322-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | HIF1A, HIF1AN, EGLN3 | SLC2A1 1235/4885KCNK3 2267/4885KCNK9 4476/4885 |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | SLC2A1 6/4885KCNK3 2898/4885KCNK9 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.